PDSB pdsbiotech.com: Enterprise Value to EBITDA Ratio

Graphic logo of PDS Biotechnology Corporation (PDSB)

PDS Biotechnology (PDSB) relies on external contractors for drug manufacturing and testing to maintain workforce mobility. The company is currently expanding its Phase II/III trial program through collaborations with US oncology centers. However, global conflicts could hinder international research and patent protection. This chart illustrates the asset's market valuation in terms of EV/EBITDA at 0.00, highlighting the current business valuation.

PDS Biotech - PDSB Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for pdsbiotech.com (PDSB)

- stock price and consensus target price:
Stock Quotes PDS Biotechnology Corporation|PDSB - Average Forecast Price
- company stock capitalization data:
Market Valuation PDS Biotechnology Corporation|PDSB - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share PDS Biotechnology|PDSB - Book Valuation of Business|Market Value to Book Value Ratio pdsbiotech.com|PDSB - Cumulative Company Assets
- debt and solvency information:
Debt to Equity PDS Biotechnology|PDSB - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio PDS Biotechnology Corporation|PDSB - Company Aggregate Debts|Debt to Book Capitalization Ratio PDS Biotechnology Corporation|PDSB - Company Long-Term Indebtedness|Company Short-Term Debt PDS Biotechnology|Quick Liquidity Indicator pdsbiotech.com
- financial results and valuation multiples details:
PDSB - Annual Net Income|Future Profit PDS Biotechnology|PDSB - Market Price to Net Income Ratio|Forward P/E Multiple PDS Biotechnology Corporation|PDSB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple PDS Biotechnology Corporation|PDSB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months PDS Biotechnology|PDSB - Earnings per share for the trailing year|Quarterly EPS earnings growth pdsbiotech.com|PDSB - Earnings growth in current year|Net earnings per share growth forecast for next year PDS Biotechnology
Fundamental company analysis:PDSB (PDS Biotechnology Corp)
Original product of PDS Biotech

For PDS Biotechnology (PDSB), whose valuation is based on the success of the Versamune platform in combating HPV-related cancers, this indicator serves as a filter between market optimism and actual operational efficiency. By analyzing the company's current EV/EBITDA multiple, an investor assesses the total enterprise value, including debt, relative to earnings before interest, taxes, depreciation, and amortization, allowing for an objective comparison of asset value against the potential for commercializing clinical data.

Competitor analysis for PDS Biotechnology

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio NEXI|TSBX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation VCNX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx